Accelerated clinical discovery using self-reported patient data collected online and a patient-matching algorithm (original) (raw)

References

  1. Ross, E. Unapproved drug use: compassionate or cause for concern? Lancet Neurol. 8, 136–137 (2009).
    Article Google Scholar
  2. Boguski, M.S., Mandl, K.D. & Sukhatme, V.P. Drug discovery. Repurposing with a difference. Science 324, 1394–1395 (2009).
    Article CAS Google Scholar
  3. Miller, R.G. et al. Outcomes research in amyotrophic lateral sclerosis: lessons learned from the amyotrophic lateral sclerosis clinical assessment, research, and education database. Ann. Neurol. 65 (Suppl 1), S24–S28 (2009).
    Article Google Scholar
  4. Regenberg, A.C., Hutchinson, L.A., Schanker, B. & Mathews, D.J. Medicine on the fringe: stem cell-based interventions in advance of evidence. Stem Cells 27, 2312–2319 (2009).
    Article Google Scholar
  5. ALSUntangled Group. ALSUntangled No. 8: Low dose naltrexone for ALS. Amyotroph. Lateral Scler. 12, 76–78 (2011).
  6. Wijesekera, L.C. & Leigh, P.N. Amyotrophic lateral sclerosis. Orphanet J. Rare Dis. 4, 3 (2009).
    Article Google Scholar
  7. Fornai, F. et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA 105, 2052–2057 (2008).
    Article CAS Google Scholar
  8. Figlewicz, D.A. Comments on Fornai et al. (PNAS/ Feb 2008). Amyotroph. Lateral Scler. 9, 125–126 (2008).
    Article Google Scholar
  9. Meininger, V., Shefner, J. & Cudkowicz, M. Lithium therapy in ALS. Amyotroph. Lateral Scler. 9, 122 (2008).
    Article Google Scholar
  10. Bedlack, R.S., Maragakis, N. & Heiman-Patterson, T. Lithium may slow progression of amyotrophic lateral sclerosis, but further study is needed. Proc. Natl. Acad. Sci. USA 105, E17 (2008).
    Article CAS Google Scholar
  11. Frost, J.H., Massagli, M.P., Wicks, P. & Heywood, J. How the Social Web Supports patient experimentation with a new therapy: the demand for patient-controlled and patient-centered informatics. AMIA Annu. Symp. Proc. 6, 217–221 (2008).
    Google Scholar
  12. Cedarbaum, J.M. et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J. Neurol. Sci. 169, 13–21 (1999).
    Article CAS Google Scholar
  13. Wicks, P. et al. Sharing health data for better outcomes on PatientsLikeMe. J. Med. Internet Res. 12, e19 (2010).
    Article Google Scholar
  14. Cudkowicz, M.E. et al. Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 11, 259–265 (2010).
    Article CAS Google Scholar
  15. Castrillo-Viguera, C., Grasso, D.L., Simpson, E., Shefner, J. & Cudkowicz, M.E. Clinical significance in the change of decline in ALSFRS-R. Amyotroph. Lateral Scler. 11, 178–180 (2010).
    Article Google Scholar
  16. Aggarwal, S.P. et al. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 9, 481–488 (2010).
    Article CAS Google Scholar
  17. Chio, A. et al. Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial. Neurology 75, 619–625 (2010).
    Article CAS Google Scholar
  18. Verstraete, E., Veldink, J.H. & van den Berg, L.H. Would riluzole be efficacious in the new ALS trial design? Lancet Neurol. 9, 949–950, author reply 950–951 (2010).
    Article CAS Google Scholar
  19. Armon, C. Is the lithium-for-ALS genie back in the bottle? Neurology 75, 586–587 (2010).
    Article Google Scholar
  20. Kriz, J., Nguyen, M.D. & Julien, J.P. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 10, 268–278 (2002).
    Article CAS Google Scholar
  21. Van Den Bosch, L., Tilkin, P., Lemmens, G. & Robberecht, W. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 13, 1067 (2002).
    Article CAS Google Scholar
  22. Gordon, P.H. et al. Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. Neurology 62, 1845 (2004).
    Article CAS Google Scholar
  23. Gordon, P.H. et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 6, 1045–1053 (2007).
    Article CAS Google Scholar
  24. Montes, J. et al. Development and evaluation of a self-administered version of the ALSFRS-R. Neurology 67, 1294–1296 (2006).
    Article CAS Google Scholar
  25. Logroscino, G. et al. Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. J. Neurol. Neurosurg. Psychiatry 79, 6–11 (2008).
    Article CAS Google Scholar
  26. Gordon, P.H. et al. Defining survival as an outcome measure in amyotrophic lateral sclerosis. Arch. Neurol. 66, 758–761 (2009).
    Article Google Scholar
  27. Call, J., Scherzer, N.J., Josephy, P.D. & Walentas, C. Evaluation of self-reported progression and correlation of imatinib dose to survival in patients with metastatic gastrointestinal stromal tumors: an open cohort study. J. Gastrointest. Cancer. 41, 60–70 (2010).
    Article CAS Google Scholar
  28. Lindstrom, M.J. & Bates, D.M. Newton-Raphson and EM algorithms for linear mixed-effects models for repeated-measures data. J. Am. Stat. Assoc. 83, 1014–1022 (1988).
    Google Scholar

Download references